doxazosin has been researched along with Cancer of Prostate in 42 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3H-Doxazosin binding sites were characterized in canine brain and human prostate homogenates using saturation experiments." | 5.28 | Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1990) |
| "Doxazosin (Doxa) is an α1-selective adrenergic receptor (ADR) antagonist widely used, alone or in combination, to treat high blood pressure, benign prostatic hyperplasia symptoms, and recently has been suggested as a potential drug for prostate cancer prevention/treatment." | 3.79 | Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats. ( Andric, SA; Janjic, MM; Kostic, TS; Stojkov, NJ, 2013) |
| "Finasteride (Fin) and Doxazosin (Dox), alone or in combination, have been widely used in treatment of benign prostatic hyperplasia (BPH) symptoms and recently have been suggested as potential drugs for prostate cancer (PCa)prevention and treatment." | 3.76 | Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. ( Acquaro, C; Carvalho, RF; Felisbino, SL; Justulin, LA; Silva, MD, 2010) |
| "Patients with prostate cancer are initially treated with surgical resection, radiation or antiandrogen therapy." | 2.42 | The role of alpha-blockers in the management of prostate cancer. ( Kyprianou, N; Rowland, RG; Tahmatzopoulos, A, 2004) |
| "Oral squamous cell carcinoma (OSCC), a global threatening disease, is reported mostly in the middle and elderly male population." | 1.91 | Anti-cell Proliferative Mechanism of Doxazosin on Human Oral Cancer Cells Through the Modulation of Antioxidant and Apoptotic Pathway. ( Li, L; Ma, F; Meng, D; Xing, D; Zhang, Y, 2023) |
| "From Feb 2011 to Jan 2012, 83 benign prostatic hyperplasia (BPH) patients with prostate volume (PV) >30 mL were enrolled in our study." | 1.43 | The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. ( Ding, J; Duan, L; Qi, J; Qian, X; Xu, D; Zhu, Y, 2016) |
| "Treatment with prazosin (30 μM) altered the expression of several cell stress-related proteins: elevating phospho-p38α and reducing S6 kinase in both cell lines." | 1.43 | Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines. ( Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C, 2016) |
| "Genome-wide analysis in the human prostate cancer cell line DU-145 identified primary downregulated targets of DZ-50, including genes involved in focal adhesion integrity (fibronectin, integrin-α6 and talin), tight junction formation (claudin-11) as well as insulin growth factor binding protein 3 (IGFBP-3) and the angiogenesis modulator thrombospondin 1 (TSP-1)." | 1.40 | Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells. ( Chen, CS; Desiniotis, A; Hensley, PJ; Kyprianou, N; Stromberg, A; Wang, C, 2014) |
| "When doxazosin treatment was added, apoptotic indices increased in a dose-dependent manner (1, 10, and 25 μ M): nonsilencing 10, 27, and 52%; Hsp27-silencing: 14, 35, and 68%; c-FLIP silencing: 21, 46, and 78%; dual silencing: 38, 76, and 92%." | 1.39 | Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells. ( Cho, HJ; Cho, JM; Kang, JY; Kim, SS; Yang, HW; Yoo, TK, 2013) |
| "Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells." | 1.38 | A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. ( Acharya, C; Ficker, E; Guo, H; Hsieh, JT; Lindner, DJ; Liu, L; MacKerell, AD; Miao, H; Myshkin, E; Page, P; Petty, A; Qin, H; Song, J; Tochtrop, GP; Wang, B, 2012) |
| "All newly diagnosed prostate cancer cases unexposed to alpha1-adrenoreceptor antagonists in the total male Veterans Affairs population during this period were also identified from the Kentucky Cancer Registry database." | 1.34 | Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. ( Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM, 2007) |
| "The doxazosin treatment did not further decrease the expression of an already low level of Bcl-2 in all prostate tumors, but it increased the expression of Bax, and the activation of caspase-3, and the cleavage of a downstream substrate, PARP." | 1.33 | Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. ( Chiang, CF; Son, EL; Wu, GJ, 2005) |
| "In doxazosin treated groups Smad-4 and IkappaB alpha expressions were higher than that of the control group." | 1.33 | [Inhibitory effect of doxazosin on the growth of transplanted tumor of prostate cancer cell PC-3 in nude mice]. ( Dong, JQ; Guo, CY; Huang, XB; Liu, SJ; Wang, XF; Xu, KX; Xu, T; Ye, HY, 2005) |
| "Maspin overexpression in prostate cancer cells resulted in an increased ability to attach to ECM-coated plates, and doxazosin treatment considerably antagonized this effect by decreasing the attachment potential to collagen and fibronectin." | 1.33 | Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. ( Kyprianou, N; Sheng, S; Tahmatzopoulos, A, 2005) |
| "Doxazosin is a quinazoline-based compound acting as an alpha-1-adrenergic inhibitor shown to induce apoptosis in prostate cancer cell lines via an alpha-1-adrenergic receptor-independent mechanism." | 1.33 | Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. ( Arencibia, JM; Bonnin, A; Del Rio, M; Lemoine, NR; Lopes, R; López-Barahona, M, 2005) |
| "Androgen independent PC-3 prostate cancer cells and PC-3 transfectant clones over expressing the apoptosis suppressor bcl-2 were used as an in vitro model." | 1.32 | Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. ( Keledjian, K; Kyprianou, N, 2003) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Doxazosin was combined either with adriamycin, etoposide or paclitaxel after its cytotoxic effects were detected in these cell lines." | 1.31 | Doxazosin: a new cytotoxic agent for prostate cancer? ( Cal, C; Gunaydin, G; Omay, SB; Ozyurt, C; Uslu, R, 2000) |
| "Our results indicate that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth." | 1.31 | Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. ( Benning, CM; Kyprianou, N, 2000) |
| "Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland." | 1.31 | Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000) |
| "3H-Doxazosin binding sites were characterized in canine brain and human prostate homogenates using saturation experiments." | 1.28 | Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 29 (69.05) | 29.6817 |
| 2010's | 11 (26.19) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Shaw, YJ | 2 |
| Yang, YT | 1 |
| Garrison, JB | 3 |
| Kyprianou, N | 13 |
| Chen, CS | 3 |
| Quaglia, W | 1 |
| Santoni, G | 1 |
| Pigini, M | 1 |
| Piergentili, A | 1 |
| Gentili, F | 1 |
| Buccioni, M | 1 |
| Mosca, M | 1 |
| Lucciarini, R | 1 |
| Amantini, C | 1 |
| Nabissi, MI | 1 |
| Ballarini, P | 1 |
| Poggesi, E | 3 |
| Leonardi, A | 1 |
| Giannella, M | 1 |
| Giardinà, D | 1 |
| Martarelli, D | 1 |
| Sagratini, G | 1 |
| Angeli, P | 1 |
| Ballinari, D | 1 |
| Gulini, U | 1 |
| Melchiorre, C | 1 |
| Pompei, P | 1 |
| Maestri, V | 1 |
| Tarozzi, A | 1 |
| Simoni, E | 1 |
| Cilia, A | 1 |
| Naldi, M | 1 |
| Nicolini, B | 1 |
| Pruccoli, L | 1 |
| Rosini, M | 1 |
| Minarini, A | 1 |
| Xing, D | 1 |
| Li, L | 1 |
| Meng, D | 1 |
| Zhang, Y | 1 |
| Ma, F | 1 |
| Stojkov, NJ | 1 |
| Janjic, MM | 1 |
| Kostic, TS | 1 |
| Andric, SA | 1 |
| Kim, SS | 1 |
| Cho, HJ | 1 |
| Cho, JM | 1 |
| Kang, JY | 1 |
| Yang, HW | 1 |
| Yoo, TK | 2 |
| Hensley, PJ | 1 |
| Desiniotis, A | 1 |
| Wang, C | 1 |
| Stromberg, A | 1 |
| Sarkar, D | 1 |
| Kumar, M | 1 |
| Xu, D | 1 |
| Ding, J | 1 |
| Zhu, Y | 1 |
| Qian, X | 1 |
| Duan, L | 1 |
| Qi, J | 1 |
| Forbes, A | 2 |
| Anoopkumar-Dukie, S | 2 |
| Chess-Williams, R | 2 |
| McDermott, C | 1 |
| Batty, M | 1 |
| Pugh, R | 1 |
| Rathinam, I | 1 |
| Simmonds, J | 1 |
| Walker, E | 1 |
| McDermott, CM | 1 |
| Spencer, B | 1 |
| Christie, D | 1 |
| Youm, YH | 1 |
| Kim, S | 1 |
| Bahk, YY | 1 |
| Liu, CM | 1 |
| Lo, YC | 1 |
| Tai, MH | 1 |
| Wu, BN | 1 |
| Wu, WJ | 1 |
| Chou, YH | 1 |
| Chai, CY | 1 |
| Huang, CH | 1 |
| Chen, IJ | 1 |
| Justulin, LA | 1 |
| Acquaro, C | 1 |
| Carvalho, RF | 1 |
| Silva, MD | 1 |
| Felisbino, SL | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Petty, A | 1 |
| Myshkin, E | 1 |
| Qin, H | 1 |
| Guo, H | 1 |
| Miao, H | 1 |
| Tochtrop, GP | 1 |
| Hsieh, JT | 1 |
| Page, P | 1 |
| Liu, L | 1 |
| Lindner, DJ | 1 |
| Acharya, C | 1 |
| MacKerell, AD | 1 |
| Ficker, E | 1 |
| Song, J | 1 |
| Wang, B | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Keledjian, K | 1 |
| Partin, JV | 1 |
| Anglin, IE | 1 |
| O'Reilly, P | 1 |
| Lee, SC | 1 |
| Ellis, RJ | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 1 |
| Tahmatzopoulos, A | 3 |
| Rowland, RG | 2 |
| Walden, PD | 1 |
| Globina, Y | 1 |
| Nieder, A | 1 |
| Hausmann, R | 1 |
| Thalmann, G | 1 |
| Reich, O | 1 |
| Steif, CG | 1 |
| Chiang, CF | 1 |
| Son, EL | 1 |
| Wu, GJ | 1 |
| Muradian, AA | 1 |
| Guo, CY | 1 |
| Wang, XF | 1 |
| Xu, KX | 1 |
| Dong, JQ | 1 |
| Huang, XB | 1 |
| Liu, SJ | 1 |
| Xu, T | 1 |
| Ye, HY | 1 |
| Sheng, S | 1 |
| Arencibia, JM | 1 |
| Del Rio, M | 1 |
| Bonnin, A | 1 |
| Lopes, R | 1 |
| Lemoine, NR | 1 |
| López-Barahona, M | 1 |
| Azadzoi, KM | 1 |
| Jewett, MA | 1 |
| Klotz, LH | 1 |
| Harris, AM | 1 |
| Warner, BW | 1 |
| Wilson, JM | 1 |
| Becker, A | 1 |
| Conner, W | 1 |
| Lane, M | 1 |
| Kimbler, K | 1 |
| Durbin, EB | 1 |
| Baron, AT | 1 |
| Cal, C | 1 |
| Uslu, R | 1 |
| Gunaydin, G | 1 |
| Ozyurt, C | 1 |
| Omay, SB | 1 |
| Benning, CM | 3 |
| Chon, J | 1 |
| Lepor, H | 1 |
| Baumann, M | 1 |
| Shapiro, E | 1 |
3 reviews available for doxazosin and Cancer of Prostate
| Article | Year |
|---|---|
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; | 2016 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoi | 2004 |
2 trials available for doxazosin and Cancer of Prostate
| Article | Year |
|---|---|
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
[Alfa-blockade with doxazosin vs tamsulozin in combination of intermittent androgen blockade in patients with prostate cancer].
Topics: Adrenergic alpha-Antagonists; Aged; Androgen Antagonists; Antineoplastic Agents; Doxazosin; Drug The | 2005 |
37 other studies available for doxazosin and Cancer of Prostate
| Article | Year |
|---|---|
Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation.
Topics: Adrenergic alpha-Antagonists; Antineoplastic Agents; Apoptosis; Cell Division; Doxazosin; Enzyme Act | 2004 |
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subt
Topics: Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Prol | 2005 |
Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agent | 2009 |
Quinazoline based α
Topics: Adrenergic alpha-1 Receptor Antagonists; Apoptosis; Cell Proliferation; Dose-Response Relationship, | 2017 |
Anti-cell Proliferative Mechanism of Doxazosin on Human Oral Cancer Cells Through the Modulation of Antioxidant and Apoptotic Pathway.
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Antioxidants; Apoptosis; Carcinoma, Squamous Cell; Cell | 2023 |
Orally applied doxazosin disturbed testosterone homeostasis and changed the transcriptional profile of steroidogenic machinery, cAMP/cGMP signalling and adrenergic receptors in Leydig cells of adult rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Androgens; Animals; Cells, Cultured; Cyclic AMP; Cyclic AMP | 2013 |
Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor | 2013 |
Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells.
Topics: Anoikis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Claudins; Down-Regulation; D | 2014 |
An interesting case of an antihypertensive causing post-prostatectomy incontinence.
Topics: Aged; Antihypertensive Agents; Doxazosin; Humans; Laparoscopy; Male; Prostate-Specific Antigen; Pros | 2015 |
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men.
Topics: Aged; Asian People; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-S | 2016 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Ce | 2016 |
Proteomic analysis of androgen-independent growth in low and high passage human LNCaP prostatic adenocarcinoma cells.
Topics: Adenocarcinoma; Androgens; Cell Extracts; Cell Line, Tumor; Cell Proliferation; Clone Cells; Doxazos | 2008 |
Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Topics: Adrenergic alpha-Antagonists; Animals; bcl-2-Associated X Protein; Cell Division; Down-Regulation; D | 2009 |
Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
Topics: Androgens; Animals; Cell Proliferation; Dihydrotestosterone; Doxazosin; Epithelial Cells; Extracellu | 2010 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.
Topics: Biocatalysis; Doxazosin; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Models, | 2012 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell | 2003 |
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.
Topics: Adrenergic alpha-Antagonists; AMP-Activated Protein Kinase Kinases; Apoptosis; Caspase 3; Caspases; | 2003 |
Pharmaceutical review.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neo | 2003 |
Male breast cancer during finasteride therapy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Carcinoma, Ductal; Do | 2004 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase.
Topics: Anoikis; Caspase 3; Caspases; Doxazosin; Focal Adhesion Kinase 2; Humans; Immunoblotting; Male; Pros | 2004 |
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind | 2004 |
Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
Topics: Adrenergic alpha-Antagonists; Androgen-Binding Protein; Animals; Antigens, CD; bcl-2-Associated X Pr | 2005 |
[Inhibitory effect of doxazosin on the growth of transplanted tumor of prostate cancer cell PC-3 in nude mice].
Topics: Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Doxazosin | 2005 |
Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Cell Adhesion; Cell Proliferation; Doxazosin; Extracellular | 2005 |
Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; | 2005 |
Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic alpha-Antagonists; Apoptosis; Caspase 8; Caspases; | 2006 |
Editorial comment on: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue.
Topics: Actins; Adrenergic alpha-Antagonists; Aged; Animals; Blotting, Western; Cyclic GMP; Cyclic GMP-Depen | 2007 |
Advances in the medical management of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyp | 2007 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Anti | 2007 |
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; C | 2007 |
Doxazosin: a new cytotoxic agent for prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxazosin; Doxorub | 2000 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis | 2000 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Rela | 2002 |
Binding and functional properties of doxazosin in the human prostate adenoma and canine brain.
Topics: Adenoma; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Brain; Dogs; Doxazosin; Humans | 1990 |